NCT03805477View on ClinicalTrials.gov

Nintedanib in Patients With Bronchiolitis Obliterans Syndrome Following Hematopoietic Stem Cell Transplantation

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 20, 2019

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
Bronchiolitis Obliterans Syndrome (BOS)Bronchiolitis Obliterans (BO)
Interventions
DRUG

Nintedanib

Nintedanib 150 mg Kps bid (oral); in order to manage adverse events, the dose of Nintedanib may be reduced from 150 mg twice daily to 100 mg twice daily

Trial Locations (3)

4031

RECRUITING

Clinic of Hematology, University Hospital Basel, Basel

RECRUITING

Clinic of Respiratory Medicine, University Hospital Basel, Basel

11471

RECRUITING

King Faisal Specialist Hospital & Research Centre, Riyadh

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER